Research programme: anti-CD160 antibodies - ElsaLys Biotech

Drug Profile

Research programme: anti-CD160 antibodies - ElsaLys Biotech

Alternative Names: anti-CD160 bispecific antibody -ElsaLys; ELB 011; ELB-012; ELB-021

Latest Information Update: 27 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator INSERM
  • Developer ElsaLys Biotech; INSERM
  • Class Antiglaucomas; Antineoplastics; Bispecific antibodies; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action CD160-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Chronic lymphocytic leukaemia; Diabetic retinopathy; Glaucoma; Solid tumours

Most Recent Events

  • 02 Jul 2018 Elsalys Biotech plans clinical development of ELB 011 for Wet-age related macular degneration and retinal vascular pathologies (Montherapy, Combination therapy) in 2020
  • 22 Feb 2018 ElsaLys Biotech enters into a license option agreement with Thea for ELB 011 in Ophthalmology
  • 18 Jul 2017 ElsaLys Biotech and DKFZ collaborate for preclinical studies for ELB 021 in B-cell leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top